Only 20–30 % of patients experience a long-term benefit from immunotherapy, but the high rate of adverse events in immunotherapies is also a matter of intense research and scientific debate
Adverse effects in immunotherapy
read more
All posts to the category
Only 20–30 % of patients experience a long-term benefit from immunotherapy, but the high rate of adverse events in immunotherapies is also a matter of intense research and scientific debate
Recap of the 8th Munich Metabolomics Symposium, November 12th, 2021
A multi-OMICS approach identified metabolic signatures related to fatty acid oxidation in bladder cancer progression.
Cancer in comparison to chemotherapy cause distinct metabolic perturbations, which both lead to the development and progression of cachexia characterized by extreme weight loss and muscle wasting.
Acylcarnitine profiles of melanoma xenografts in mice could be a step towards a new treatment.